Wegovy savings card: eligibility, terms and price in 2026

Novo Nordisk runs two separate price routes for Wegovy, and they rarely overlap. If your commercial plan covers Wegovy, the Savings Offer lowers your copay. If it does not, or you choose to pay outside insurance, NovoCare Pharmacy sells it at a fixed self-pay price. Every figure below is as shown on Novo Nordisk pages on Oct 19, 2026; programs change.

To model your own monthly and yearly spend, use the semaglutide cost calculator. For the drug itself, see the semaglutide hub.

Who qualifies for the Wegovy Savings Offer

The Savings Offer is a manufacturer copay card. The terms on WegovyTerms set out who can use it (Novo Nordisk, Oct 19, 2026):

• Commercial insurance with Wegovy coverage. The offer is for patients with commercial insurance who have coverage for Wegovy. It does not apply when the entire cost of the prescription is reimbursable by an insurance plan.
• No government drug coverage. You are not eligible if you are enrolled in any federal or state health care program with prescription drug coverage. The terms name Medicaid, Medicare, VA, DOD and TRICARE.
• Some plans are not “government” for this offer. The terms say Federal Employees Health Benefits (FEHB) plans, Affordable Care Act (health exchange) plans and state employee plans are not federal or state government programs for purposes of the offer.
• All current doses. The covered products are Wegovy injection 0.25, 0.5, 1, 1.7, 2.4 mg and HD 7.2 mg, and Wegovy tablets 1.5, 4, 9 and 25 mg.
• Where it works. The offer is valid only in the United States and its territories. In Massachusetts, availability depends on state law at the time you present it.
• Not cash. The offer cannot be redeemed for cash and is not health insurance.

Does the Wegovy savings card expire?

The terms viewed on Oct 19, 2026 state no expiration date for the copay offer. They say it may be rescinded, revoked or amended at any time, and each Novo program footnote adds that Novo Nordisk “reserves the right to modify or cancel this program at any time” (Novo Nordisk, Oct 19, 2026). Treat the card as open-ended but not guaranteed.

How the $25 and $100 limits work

The two numbers interact. The card pays down your copay by up to $100 per 1-month prescription, but it will not take you below $25. Longer fills have higher caps: $200 for a 2-month prescription and $300 for a 3-month prescription (Novo Nordisk, Oct 19, 2026).

The rows are worked examples, not quotes. Your actual copay depends on your plan’s tier, deductible and coinsurance. A high-deductible plan can leave a large copay early in the year, and the $100 cap still applies.

Self-pay prices through NovoCare Pharmacy

If your plan does not cover Wegovy, the $25 card does not help. Novo routes these patients to NovoCare Pharmacy self-pay pricing (Novo Nordisk, Oct 19, 2026). As shown on Oct 19, 2026:

• New patients (new to the Savings Offer or NovoCare Pharmacy) pay $199 per month for each of the first two monthly fills of 0.25 mg and 0.5 mg (Novo Nordisk, Oct 19, 2026).
• After that, the pen is $349 per month for 0.25, 0.5, 1, 1.7 or 2.4 mg, and $399 per month for Wegovy HD 7.2 mg (Novo Nordisk, Oct 19, 2026).
• Deadline for the $199 price. The NovoCare Pharmacy terms require the prescription to be written on or before Dec 31, 2026, received by the pharmacy by the end of that day, and shipped on or before Jan 31, 2027 (Novo Nordisk, Oct 19, 2026).

The $199 introductory price and the $349 standard price date from November 2025, according to Novo Nordisk’s 2025 Annual Report, which said the intro offer then ran through March 31, 2026 (Novo Nordisk, Feb 2026). It has since been extended to Dec 31, 2026. TrumpRx.gov, a U.S. government page, lists the same new-patient offer as available for 2 monthly fills between Nov 17, 2025 and Dec 31, 2026 (TrumpRx.gov, Oct 19, 2026).

Self-pay purchases happen outside your insurance plan. The NovoCare terms say they cannot be submitted for reimbursement under government programs (Novo Nordisk, Oct 19, 2026). On Mar 9, 2026, Novo also announced an agreement for a telehealth company to offer branded Wegovy and Ozempic at Novo’s self-pay prices (Novo Nordisk, Mar 9, 2026). We do not list or rank sellers.

Wegovy pill prices

The once-daily Wegovy tablet has its own self-pay ladder, priced per 30-tablet bottle (Novo Nordisk, Oct 19, 2026):

The day ranges come from the Wegovy prescribing information (revised 6/2026), which steps the tablet up every 30 days to a 25 mg maintenance dose (Novo Nordisk, Jun 18, 2026). The commercial copay offer also covers all four tablet strengths.

List price today and in 2027

List price is the manufacturer’s price before insurer rebates or discounts. It matters mainly if you pay coinsurance (a percentage) or are still in your deductible.

• Now: $1,349.02 per package for the Wegovy pen, Wegovy HD pen and Wegovy pill (Novo Nordisk, Oct 19, 2026).
• From Jan 1, 2027: on Feb 24, 2026, Novo Nordisk announced a list price of $675 per month across Wegovy, Ozempic and Rybelsus (Novo Nordisk, Feb 24, 2026).
• Self-pay is unchanged by that cut. The same release says the list-price changes “do not have an impact on direct-to-patient, self-pay prices.”

If you pay 25% coinsurance, for example, the 2027 list price would roughly halve the base your share is calculated on. Your plan’s negotiated price may differ from list, so ask your plan.

Medicare, Medicaid and the GLP-1 Bridge

Medicare and Medicaid enrollees cannot use the $25 Savings Offer (Novo Nordisk, Oct 19, 2026). Two other routes exist:

• Medicare GLP-1 Bridge. Novo Nordisk says eligible Medicare patients can get Wegovy pen and pill for $50 per month between July 1, 2026 and December 31, 2027 (Novo Nordisk, Oct 19, 2026). The fine print limits it to patients prescribed Wegovy for a covered FDA-approved indication. Novo’s July 1, 2026 release describes it as a $50 monthly copay for eligible beneficiaries (Novo Nordisk, Jul 1, 2026). CMS, not Novo, sets the eligibility criteria. This is a federal program, not a Novo savings card.
• Self-pay. Government beneficiaries can still use the NovoCare self-pay prices, but those purchases sit outside the plan.

What we could not verify: wegovy.com says the Bridge covers “all dose strengths of both Wegovy pen and pill,” but the July 1, 2026 press release does not mention Wegovy HD 7.2 mg by name. Whether HD is included at $50 is unconfirmed. Ask your Part D plan before you rely on it.

Which route costs less: a 12-month example

These totals are our arithmetic on the self-pay prices shown on Oct 19, 2026. They assume a new patient who starts on 0.25 mg before the Dec 31, 2026 deadline and follows the label’s 4-week steps (Novo Nordisk, Jun 18, 2026).

The HD row is illustration only. The label allows 7.2 mg only for adults on the weight-reduction indication who have tolerated 2.4 mg for at least 4 weeks (Novo Nordisk, Jun 18, 2026). See the Wegovy dosing schedule for the full ladder, and plan dose timing with the semaglutide titration calculator.

Compounded semaglutide is not a cheaper Wegovy

Lower-priced compounded semaglutide is a different product. The FDA states that “compounded drugs are not approved by FDA” (FDA, Apr 1, 2026). It is not interchangeable with Wegovy, and the Savings Offer and NovoCare prices apply only to the FDA-approved brand.

Before you enroll

1. Ask your plan whether Wegovy is on the formulary and whether prior authorization is needed. Coverage decides which route applies.
2. If covered, enroll in the Savings Offer through Novo Nordisk and give the card details to your pharmacy.
3. If not covered, compare the self-pay price with your plan price. The wegovy.com page suggests asking your pharmacist to compare all pricing options before pickup (Novo Nordisk, Oct 19, 2026).
4. Talk to your prescriber about which dose and presentation fits your treatment; price tiers differ for HD and the pill.

For the same breakdown on the sister brand, see the Ozempic savings card guide. For tirzepatide, see the Zepbound savings card guide.